Olema Pharmaceuticals (OLMA) Stock Forecast, Price Target & Predictions
OLMA Stock Forecast
Olema Pharmaceuticals stock forecast is as follows: an average price target of $28.50 (represents a 140.30% upside from OLMA’s last price of $11.86) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
OLMA Price Target
The average price target for Olema Pharmaceuticals (OLMA) is $28.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $27.00. This represents a potential 140.30% upside from OLMA's last price of $11.86.
OLMA Analyst Ratings
According to 3 Wall Street analysts, Olema Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for OLMA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Olema Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 24, 2024 | Richard Law | Goldman Sachs | $27.00 | $11.91 | 126.70% | 127.66% |
| May 16, 2024 | Emily Bodnar | H.C. Wainwright | $30.00 | $9.85 | 204.57% | 152.95% |
| Apr 02, 2024 | Richard Law | Goldman Sachs | $24.00 | $10.89 | 120.39% | 102.36% |
The latest Olema Pharmaceuticals stock forecast, released on Oct 24, 2024 by Richard Law from Goldman Sachs, set a price target of $27.00, which represents a 126.70% increase from the stock price at the time of the forecast ($11.91), and a 127.66% increase from OLMA last price ($11.86).
Olema Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 3 |
| Avg Price Target | $27.00 | $27.00 | $27.00 |
| Last Closing Price | $11.86 | $11.86 | $11.86 |
| Upside/Downside | 127.66% | 127.66% | 127.66% |
In the current month, the average price target of Olema Pharmaceuticals stock is $27.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 127.66% increase as opposed to Olema Pharmaceuticals's last price of $11.86. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 24, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 24, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Jun 04, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 02, 2024 | Goldman Sachs | - | Buy | Initialise |
| Jun 09, 2022 | H.C. Wainwright | - | Buy | Upgrade |
Olema Pharmaceuticals's last stock rating was published by H.C. Wainwright on Oct 24, 2024. The company gave OLMA a "Buy" rating, the same as its previous rate.
Olema Pharmaceuticals Financial Forecast
Olema Pharmaceuticals Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Olema Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. OLMA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Olema Pharmaceuticals EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict OLMA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Olema Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Olema Pharmaceuticals Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-38.97M | $-35.57M | $-33.80M | $-41.25M | $-38.27M | $-35.46M | $-34.52M | $-32.27M | $-34.72M | $-32.14M | $-30.57M |
| High Forecast | $-38.97M | $-35.57M | $-33.80M | $-41.25M | $-38.27M | $-35.46M | $-34.52M | $-32.27M | $-34.72M | $-27.71M | $-30.57M |
| Low Forecast | $-38.97M | $-35.57M | $-33.80M | $-41.25M | $-38.27M | $-35.46M | $-34.52M | $-32.27M | $-34.72M | $-34.91M | $-30.57M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Olema Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. OLMA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Olema Pharmaceuticals SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Olema Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to OLMA last annual SG&A of $NaN (undefined).
Olema Pharmaceuticals EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.69 | $-0.63 | $-0.60 | $-0.73 | $-0.68 | $-0.63 | $-0.61 | $-0.57 | $-0.62 | $-0.57 | $-0.54 |
| High Forecast | $-0.69 | $-0.63 | $-0.60 | $-0.73 | $-0.68 | $-0.63 | $-0.61 | $-0.57 | $-0.62 | $-0.49 | $-0.54 |
| Low Forecast | $-0.69 | $-0.63 | $-0.60 | $-0.73 | $-0.68 | $-0.63 | $-0.61 | $-0.57 | $-0.62 | $-0.62 | $-0.54 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Olema Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to OLMA previous annual EPS of $NaN (undefined).
Olema Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics | $1.08 | $8.75 | 710.19% | Buy |
| ZNTL | Zentalis Pharmaceuticals | $3.73 | $21.86 | 486.06% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| MOLN | Molecular Partners | $6.06 | $29.00 | 378.55% | Buy |
| PEPG | PepGen | $6.79 | $29.50 | 334.46% | Buy |
| FENC | Fennec Pharmaceuticals | $4.65 | $15.75 | 238.71% | Buy |
| SANA | Sana Bio | $3.76 | $12.00 | 219.15% | Buy |
| LRMR | Larimar Therapeutics | $7.57 | $20.33 | 168.56% | Buy |
| ERAS | Erasca | $2.87 | $7.00 | 143.90% | Buy |
| OLMA | Olema Pharmaceuticals | $11.86 | $28.50 | 140.30% | Buy |
| MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| DSGN | Design Therapeutics | $5.32 | $9.67 | 81.77% | Buy |
| PHVS | Pharvaris | $23.93 | $39.67 | 65.78% | Buy |
| CNTA | Centessa Pharmaceuticals | $15.89 | $21.67 | 36.38% | Buy |
| IRON | Disc Medicine | $58.25 | $66.86 | 14.78% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
OLMA Forecast FAQ
Is Olema Pharmaceuticals a good buy?
Yes, according to 3 Wall Street analysts, Olema Pharmaceuticals (OLMA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of OLMA's total ratings.
What is OLMA's price target?
Olema Pharmaceuticals (OLMA) average price target is $28.5 with a range of $27 to $30, implying a 140.30% from its last price of $11.86. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Olema Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for OLMA stock, the company can go up by 140.30% (from the last price of $11.86 to the average price target of $28.5), up by 152.95% based on the highest stock price target, and up by 127.66% based on the lowest stock price target.
Can Olema Pharmaceuticals stock reach $20?
OLMA's average twelve months analyst stock price target of $28.5 supports the claim that Olema Pharmaceuticals can reach $20 in the near future.
What is Olema Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $27 price target for Olema Pharmaceuticals (OLMA) this month, up 127.66% from its last price of $11.86. Compared to the last 3 and 12 months, the average price target increased by 127.66% and increased by 127.66%, respectively.
What are Olema Pharmaceuticals's analysts' financial forecasts?
Olema Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-141M (high $-141M, low $-141M), average SG&A $0 (high $0, low $0), and average EPS is $-2.497 (high $-2.497, low $-2.497). OLMA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-150M (high $-150M, low $-150M), average SG&A $0 (high $0, low $0), and average EPS is $-2.658 (high $-2.658, low $-2.658).